No products in the cart.

Chapter 12- Drug Therapy for the Treatment of Cancer

For Any Test Bank, Solution Manual Or Exam, Contact Us At, nurseguidehub@gmail.com

$1.99

Chapter 12- Drug Therapy for the Treatment of Cancer

 

Complete Chapter Questions With Answers

 

Sample Questions Are Posted Below 

 

1. A patient has been diagnosed with a brain tumor and is dealing with this diagnosis by seeking detailed information about cancer. The nurse would explain to the patient that cancer is essentially a result of the disruption of the
  A) cell cycle.
  B) cell wall.
  C) lymphatic system.
  D) immune system.
  Ans: A
  Feedback:
  Malignant cells have lost the normal genetic regulation that controls cell growth, invading normal tissues and taking blood and nutrients away from these tissues. In essence, the cell cycle has been pathologically disrupted.

 

 

2. A 49-year-old patient is diagnosed with ovarian cancer. What is a characteristic of malignant cells that differentiates them from normal body cells?
  A) Cancerous cells do not require an energy source in order to proliferate.
  B) Cancerous cells grow in an uncontrollable fashion.
  C) Cancerous cells have a theoretically infinite lifespan.
  D) Cancerous cells are not responsive to the presence of drugs.
  Ans: B
  Feedback:
  Malignant cells have lost the normal genetic regulation that controls cell growth, invading normal tissues and taking blood and nutrients away from these tissues. They grow in an uncontrolled fashion without regard to growth regulation signals (e.g., contact with other cells) that stop the growth of normal cells. Cancerous cells, like all cells, have a finite lifespan and need energy. Cancerous cells are responsive to drugs; this is the rationale for treatment with antineoplastics.

 

 

3. A patient with a diagnosis of bladder cancer is started on a chemotherapeutic regimen that includes three agents. What is the rationale for using multiple antineoplastic agents?
  A) The use of three agents decreases the development of cell resistance.
  B) The use of three agents increases adherence to treatment.
  C) The use of three agents increases the serum levels of one of the agents.
  D) The use of three agents decreases the total adverse effects.
  Ans: A
  Feedback:
  Most chemotherapy regimens involve a combination of drugs with different actions at the cellular level, which destroys a greater number of cancer cells and reduces the risk of the cancer developing drug resistance.

 

 

4. A patient has undergone an aggressive chemotherapeutic regimen to treat leukemia. The patient develops gastrointestinal upset, hypertension, and paresthesias. What syndrome is the patient developing?
  A) Fröhlich’s syndrome
  B) Epidermal nevus syndrome
  C) Irritable bowel syndrome
  D) Tumor lysis syndrome
  Ans: D
  Feedback:
  With the treatment of leukemias and lymphomas, a serious, life-threatening adverse effect called tumor lysis syndrome may occur. This syndrome occurs when large numbers of cancer cells are killed or damaged, releasing their contents into the blood stream. The patient may have metabolic imbalances, which include gastrointestinal upset, hypertension, and paresthesias. Fröhlich’s syndrome is noted in adolescent boys who have an increase in fat and atrophy of the genitals. Epidermal nevus syndrome is associated with multiple nevi. Irritable bowel syndrome is marked by abdominal pain and disturbances of evacuation.

 

 

5. A patient develops tumor lysis syndrome during the administration of chemotherapy agents. Which of the following treatments is implemented to resolve this health problem?
  A) Administration of potassium IV
  B) Administration of anti-inflammatory agents
  C) Limiting of fluid intake and reduction in IV fluid rate
  D) Administration of IV normal saline and sodium bicarbonate
  Ans: D
  Feedback:
  The patient experiencing lysis syndrome should receive regular insulin and IV sodium bicarbonate. The patient suffers from hyperkalemia and should not be administered potassium. The patient would not be administered anti-inflammatory agents. The patient should be aggressively hydrated and thus should not have fluids limited or decreased.

 

Additional information

Add Review

Your email address will not be published. Required fields are marked *